838 reports of this reaction
4.7% of all DRONEDARONE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for DRONEDARONE, manufactured by Sanofi-Aventis U.S. LLC. There are 838 FDA adverse event reports linking DRONEDARONE to DYSPNOEA. This represents approximately 4.7% of all 17,724 adverse event reports for this drug.
Patients taking DRONEDARONE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among DRONEDARONE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for DRONEDARONE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 838 FDA reports for DRONEDARONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 4.7% of all adverse event reports for DRONEDARONE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking DRONEDARONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.